Moreover, the launch of its gene therapy for Sickle Cell Disease (SCD), Lyfgenia, is expected to gain momentum with a good number of qualified treatment centers ready, giving Bluebird Bio a first-mover advantage in the SCD market. This optimistic outlook on patient starts and the launch ...
Moreover, the launch of its gene therapy for Sickle Cell Disease (SCD), Lyfgenia, is expected to gain momentum with a good number of qualified treatment centers ready, giving Bluebird Bio a first-mover advantage in the SCD market. This optimistic outlook on patient starts ...
The primary driver behind the positive stance is the proposed acquisition of RayzeBio, which significantly bolsters BMY’s oncology pipeline by adding radiopharmaceutical therapeutics for the treatment of solid tumors. This move is seen as a diversification strategy that could potentiall...
Challenges and Lessons from Bariatric/Metabolic SurgeryMicrobiota in Human DiseaseMultidisciplinarity and Interdisciplinary Basics in Mental HealthNew Insights into Diseases with Cognitive Impairment: Development, Genesis, and TreatmentNew Perspectives on the Measurement of Free Light Chains in the Different Mat...